Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VNU cancels IMS deal

This article was originally published in The Tan Sheet

Executive Summary

Dutch publishing company VNU has agreed to terminate the merger with IMS Health after nearly 50% of shareholders voiced opposition to the deal, the Haarlem, Netherlands-based firm announces Nov. 17. The deal would have needed approval from more than half of shareholders in order to go through, VNU explained. The company will pay a termination fee of $15 mil. to IMS due to the falling-through of the deal. VNU announced the $7 bil. merger plans in July, but vacillated on the acquisition during the week of Nov. 7 (1"The Tan Sheet" Nov. 14, 2005, In Brief)...

You may also be interested in...



IMS/VNU merger

VNU is considering amending or terminating its merger agreement with IMS Health, the company says Nov. 7. The two firms agreed to the $7 bil. merger in July and expected the deal to close in early 2006 (1"The Tan Sheet" July 18, 2003, p. 9). However, Netherlands-based VNU says "shareholders claiming to represent 48% of VNU's outstanding shares [said] they would not support the transaction under any circumstances." VNU is AC Nielsen's parent company and provides consumer, marketing and media information to the healthcare industry; IMS Health focuses primarily on Rx healthcare. "Various possible alternatives" have been discussed including the deal's revision, VNU says...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

Topics

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel